Development of Midostaurin as a Tyrosine Kinase Inhibitor
Author:
Publisher
Springer New York
Link
http://link.springer.com/content/pdf/10.1007/978-1-4939-1393-0_10
Reference74 articles.
1. Alkan SS et al (1993) Effects of a new protein kinase C inhibitor CGP 41251 on T cell functions: inhibition of activation, growth, and target cell killing. Cell Immunol 150(1):137–148
2. Auclair D et al (2007) Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21(3):439–445
3. Barry EV et al (2007) Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood 110(13):4476–4479
4. Bienz M et al (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype.[erratum appears in Clin Cancer Res 2005 Aug 1;11(15):5659]. Clin Cancer Res 11(4):1416–1424
5. Brown P et al (2004) Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood 104(6):1841–1849
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploring the Potential of siRNA Delivery in Acute Myeloid Leukemia for Therapeutic Silencing;Nanomaterials;2023-12-18
2. FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms;RSC Medicinal Chemistry;2022
3. Midostaurin: First Global Approval;Drugs;2017-06-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3